Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed EBITDA Margin for 8 consecutive years, with 404.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 27230.0% year-over-year to 404.1%, compared with a TTM value of 80.19% through Dec 2025, down 2705.0%, and an annual FY2025 reading of 80.19%, down 2705.0% over the prior year.
  • EBITDA Margin was 404.1% for Q4 2025 at Arcturus Therapeutics Holdings, down from 78.4% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 73.21% in Q4 2022 and bottomed at 2727.69% in Q2 2021.
  • Average EBITDA Margin over 5 years is 541.79%, with a median of 79.0% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -228570bps in 2021, then soared 264810bps in 2022.
  • Year by year, EBITDA Margin stood at 667.29% in 2021, then soared by 111bps to 73.21% in 2022, then plummeted by -152bps to 37.94% in 2023, then tumbled by -247bps to 131.8% in 2024, then crashed by -207bps to 404.1% in 2025.
  • Business Quant data shows EBITDA Margin for ARCT at 404.1% in Q4 2025, 78.4% in Q3 2025, and 32.44% in Q2 2025.